#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Liposarcoma metastatic Glomerulonephritis membranoproliferative Dementia Necrotising myositis Adult T-cell lymphoma/leukaemia refractory Complex regional pain syndrome B-cell small lymphocytic lymphoma recurrent Synovial sarcoma Oropharyngeal cancer recurrent Leukodystrophy Chronic lymphocytic leukaemia recurrent Ventricular fibrillation Proteus syndrome Hepatitis D Cryoglobulinaemia More trials…

    Learn about Rare Diseases

    Alternating hemiplegia of childhood – Trials in Disease Wiskott-Aldrich syndrome – Treatment Cerebral arteriovenous malformation haemorrhagic – Diagnostics Arterial tortuosity syndrome – Treatment Lymphatic malformation – Life with Disease Vascular malformation – Treatment Mucous membrane pemphigoid – Life with Disease Glomerulonephritis membranoproliferative – Life with Disease Hereditary angioedema – Life with Disease Hereditary angioedema – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    SGT-003 Db-Oto-5 Tilsotolimod Sodium Sorafenib Tosilate Bictegravir Human Vaccinia Immunoglobulin Imiglucerase Methionine Tildacerfont Eo2317 Fingolimod Hydrochloride Siplizumab Nimotuzumab Rozanolixizumab Sepiapterin Ripretinib Fazirsiran Poltreg-T1D Losmapimod Clemizole Hydrochloride More therapies…

    Learn about Your Condition

    Marginal zone lymphoma Biliary tract operation Chronic granulomatous disease Myofascial pain syndrome Bile duct cancer Spondylolisthesis Pelizaeus-Merzbacher disease Hot flush Staphylococcal infection Athetosis Testicular germ cell tumour Small intestine adenocarcinoma Thalassaemia Acute leukaemia Neuropathy peripheral More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Colitis ulcerative

  • A study testing duvakitug for patients with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • Study of MT-501 in patients with active Crohn’s Disease or Ulcerative Colitis: A Phase 2 safety and effectiveness trial

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    • Crohn’s disease
    Belgium Bulgaria Croatia Czechia Germany Italy +2

  • Study of SAR442970 to treat moderate to severe ulcerative colitis in adults

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Sar442970
    Czechia France Germany Hungary Poland Spain

  • Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Risankizumab
    Belgium Germany Greece Italy Spain Sweden

  • Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn’s disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Vedolizumab
    Belgium Bulgaria Denmark Ireland Italy The Netherlands +4
Previous Page
1 2 3 4 5 … 20
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!